SteriPlas will be presented at the ISMCS 2023
Congratulations to Mr Thomas Schlöglhofer who has been invited to speak at the International Society for Mechanical Circulatory Support Scientific Congress (ISMCS) on Wednesday 1st November 2023.
His presentation, “Cold Atmospheric Plasma for Driveline Infection Treatment” will focus on the benefits of the SteriPlas for LVAD infections.
Our medical device has proven efficacy for the treatment of deep LVAD infections with the presence of biofilm. There is growing interest to use our SteriPlas Cold Plasma for LVAD infections due to its quick ability to destroy bacteria protected within biofilm deep within driveline cavity. This is regardless of the type of bacteria or its resistance profile. As LVAD infections can be healed in as quick as 1 week, it provides stability of the independent system and a better quality of life for patients with LVADs.
For more information about the SteriPlas, our clinical evidence or a free trial at your hospital contact us at info@adtecplasma
The Leader of Cold Plasma
There is expanding interest of our medical device for the treatment of chronic diabetic foot ulcers, deep sternal wounds and LVAD infections. We wish to remind you that if you are a Health Care Professional seeking to learn more about our medical device then please do get in contact with us. A member of our team will be able to show the full benefits and safety of using our medical device to treat these complicated conditions, with no side effects.
As Adtec Healthcare remains the leader of cold plasma medicine, we are lucky to be able to boast a wide clinical bibliography collection that really makes us stand out amongst the rest. We were the first company worldwide to do clinical trials of cold plasma on chronic wounds. Our clinical trials data has paved way in today’s medicine to show cold plasma as the go-to alternative for infection management.
If you are interested to bring the benefits of cold plasma to your patients, please email us at info@adtecplasma.com
How does the Adtec SteriPlas work so effectively?
Our patented cold plasma therapy utilises a physical mode of action approach delivered from an indirect microwave plasma source. Our cold argon plasma is an electrically charged and ionised gas that consists of charged particles, UV light and reactive oxygen and nitrogen species with the latter created as a by-product. They all work collectively to physically rupture the structure of bacteria even if they are protected within biofilm. Regardless of the type of bacteria, its resistance profile or whether they are Gram-positive or Gram-negative our cold plasma works quickly and effectively to destroy them. This has the leading advantage over conventional therapies such as antibiotics that rely on a chemical mode of action approach.
Although antibiotics have been a pivotal part of today’s medicine, they also contribute towards antimicrobial resistance rates particularly because bacteria can develop resistance such as those observed with diabetic foot ulcers that can often lead to amputations as a result.
However, as well as being fast-acting and effective, our cold plasma has shown that a primary or secondary resistance is unlikely to be developed due to its physical mode of action.
Mr Schlöglhofer to present SteriPlas at the ISHLT
Congratulations to Thomas Schlöglhofer from the Medical University of Vienna for his continued success of using our medical device to treat infections in LVAD patients. He will be presenting at The International Society for Heart and Lung Transplantation (ISHLT) conference in April to deliver the great results he has so far achieved.
His presentation, “Cold Atmospheric Plasma Therapy: A Powerful Tool for Treating Driveline Infections in Left Ventricular Assist Device Patients” will be during the “Bugs, Drugs, and Thugs: Fighting Infection in VADs Any Way We Can” Session on Wednesday 19th April between 5:30 PM - 6:30 PM.
We hope you will be there too to see him deliver his promising results.
For more information on how our medical device is fighting against multi resistant bacteria and biofilm in LVAD patients.
Invited to speak at the ICCAC meeting on 10th January
We are honoured to be invited to speak at The International Consortium of Circulatory Assist Clinicians (ICCAC) meeting tomorrow. Our presentation will focus on the strong benefits of the Adtec SteriPlas cold plasma for the management and healing of LVAD infections. With growing interest for an alternative therapy to failing antibiotics, the SteriPlas has been storming the medical market because of its accelerated healing, safe, effective, and harmless properties all of which will be discussed tomorrow at 3.30pm (CET).
Please contact us at info@adtecplasma.com for more information.
Cold Plasma Diabetic Foot Ulcer Clinical Trial Published
Congratulations to Dr Cornelia Wiegand for her published clinical trial paper, “The efficacy of non-thermal gas plasma in the treatment of diabetic foot ulcers stalled by subclinical, biofilm-related wound infection”. This clinical trial paper features the use of our SteriPlas Cold Plasma medical device for the treatment of chronic DFUs infected with biofilm.
The parameters of this study were set much higher than a normal study, with there being a much higher standard of care given (3x per week) vs a typical outpatient setting of 1x weekly.
We wanted to show that even when chronic diabetic foot ulcers are subjected to more frequent outpatient visits with biopsies and swabs included (something not often collected during standard outpatient visits), SteriPlas Cold Plasma still prevails as the successful treatment method due to its physical mode of action and ability to kill all types of bacteria protected within biofilm.
Advanced Wound Care Summit Europe 2022
It was an honour to present at the Advanced Wound Care Summit Europe conference this week. Our extensive knowledge and library of clinical trials and our history as the experienced leader of Cold Plasma medicine was presented to the audience to bring light to the positive benefits of Adtec Cold Plasma devices.
If you would like to hear more about our efficacy and strengths for wounds, surgical site infections and medical dermatology, send us a PM or email us at info@adtecplasma.com
Presenting at The Advanced Wound Care Summit Europe
We’re looking forward to the Advanced Wound Care Summit Europe conference. On the 13th December, our Managing Director, Mary McGovern, will be presenting “Cold Plasma Medicine – Clinical Trials and Regulatory Challenges” where she will explain the importance of clinical trials to test the safety and efficacy of a medical device and the challenges that one can expect.
Since we were the first company worldwide to introduce cold plasma treatment on wounds in clinical trials, it comes to no surprise that we have good experience in this field. Adtec Healthcare boasts a wide collection of clinical trials and studies of our SteriPlas cold plasma medical device to authenticate the efficacy, safety and no side effects claims that we state. We have proven clinical efficacy of managing infections in diabetic foot ulcers and surgical site infections where other treatments have failed.
Evident to our success, this is why Adtec Healthcare’s clinical trials and studies are often referenced by other cold plasma manufacturers who do not have their own clinical studies. With patient safety in mind, clinical trials proving the efficacy must be completed by each manufacturer for the technology used in their device.
New Wound Management of Driveline Infections with Cold Atmospheric Plasma
We’re ecstatic to see Dr Jamila Kremer’s publication, “New Wound Management of Driveline Infections with Cold Atmospheric Plasma” is now live for public viewing. The paper can be viewed here: https://doi.org/10.3390/jcdd9110405.
The use of our Adtec cold plasma medical device has greatly benefitted her LVAD infection patients treated at the University Heidelberg Hospital since 2019. The results stipulate a stronger infection management advantage over conventional therapy alone for LVAD infections. This is coupled with the benefit of our cold plasma being safe, painless, contact-free and free from side effects.
Driveline infections are the most prevalent infections and reported in up to 60% of LVAD patient cases. Infection of the LVAD system is the fourth most common cause of death within one year after implantation. Dr Kremer’s publication documents Adtec cold plasma treated patients showed a 100% survival rate.
For more information about the benefits of our Cold Plasma medical device, contact us at info@adtecplasma.com
Poster presentation at the DFSG 2022
Did you see Dr Pierides' poster presentation yesterday at the DFSG Diabetic Foot Study Group conference? The poster featured the Adtec SteriPlas success in treating chronic infected diabetic foot ulcers.
The SteriPlas replaced the use of antibiotics for these heavily infected and impacted wounds and had shown remarkable success.
